258 related articles for article (PubMed ID: 33993204)
1. Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study.
Secemsky EA; Shen C; Schermerhorn M; Yeh RW
JAMA Intern Med; 2021 Aug; 181(8):1071-1080. PubMed ID: 33993204
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices.
Secemsky EA; Kundi H; Weinberg I; Jaff MR; Krawisz A; Parikh SA; Beckman JA; Mustapha J; Rosenfield K; Yeh RW
JAMA Cardiol; 2019 Apr; 4(4):332-340. PubMed ID: 30747949
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Hess CN; Patel MR; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Fanelli F; Yeh RW; Secemsky EA; Beckman JA; Mauri L; Govsyeyev N; Capell WH; Brackin T; Berkowitz SD; Muehlhofer E; Haskell LP; Hiatt WR; Bonaca MP
J Am Coll Cardiol; 2021 Nov; 78(18):1768-1778. PubMed ID: 34711335
[TBL] [Abstract][Full Text] [Related]
4. An indirect comparison by Bayesian network meta-analysis of drug-coated devices versus saphenous vein graft bypass in femoropopliteal arterial occlusive disease.
Zhang R; Ni L; Zeng R; Lai Z; Di X; Zhao Z; Xie Z; Wang X; Ma B; Liu C
J Vasc Surg; 2021 Aug; 74(2):478-486.e11. PubMed ID: 33600930
[TBL] [Abstract][Full Text] [Related]
5. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
6. Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease.
Long CA; Zepel L; Greiner MA; Hammill BG; Patel MR; Jones WS
Am Heart J; 2019 Nov; 217():42-51. PubMed ID: 31473326
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of the SAFE-PAD Study.
Secemsky EA; Raja A; Shen C; Valsdottir LR; Schermerhorn M; Yeh RW;
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007040. PubMed ID: 33435732
[TBL] [Abstract][Full Text] [Related]
8. Editor's Choice - Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Katsanos K; Spiliopoulos S; Teichgräber U; Kitrou P; Del Giudice C; Björkman P; Bisdas T; de Boer S; Krokidis M; Karnabatidis D
Eur J Vasc Endovasc Surg; 2022 Jan; 63(1):60-71. PubMed ID: 34326002
[TBL] [Abstract][Full Text] [Related]
9. Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel-Coated Devices: Insights From the Veterans Health Administration.
Gutierrez JA; Rao SV; Jones WS; Secemsky EA; Aday AW; Gu L; Schulteis RD; Krucoff MW; White R; Armstrong EJ; Banerjee S; Tsai S; Patel MR; Swaminathan RV
J Am Heart Assoc; 2021 Feb; 10(4):e018149. PubMed ID: 33554613
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs.
Kayssi A; Al-Atassi T; Oreopoulos G; Roche-Nagle G; Tan KT; Rajan DK
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011319. PubMed ID: 27490003
[TBL] [Abstract][Full Text] [Related]
12. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
[TBL] [Abstract][Full Text] [Related]
13. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of drug-coated devices for peripheral revascularisation.
Secemsky EA; Barrette E; Bockstedt L; Bonaca MP; Hess CN; Hanson T; Monteiro J; Manda B; Yeh RW
EuroIntervention; 2021 Sep; 17(7):590-598. PubMed ID: 33342764
[TBL] [Abstract][Full Text] [Related]
15. Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.
Haine A; Schmid MJ; Schindewolf M; Lenz A; Bernhard SM; Drexel H; Baumgartner I; Dopheide JF
Eur J Vasc Endovasc Surg; 2019 Dec; 58(6):865-873. PubMed ID: 31668949
[TBL] [Abstract][Full Text] [Related]
16. Association of Clinical Setting With Sociodemographics and Outcomes Following Endovascular Femoropopliteal Artery Revascularization in the United States.
Raja A; Wadhera RK; Choi E; Chen S; Shen C; Figueroa JF; Yeh RW; Secemsky EA
Circ Cardiovasc Qual Outcomes; 2023 Jan; 16(1):e009199. PubMed ID: 36472193
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease.
Kim TI; Kiwan G; Mohamedali A; Zhang Y; Mena-Hurtado C; Mojibian H; Guzman RJ; Ochoa Chaar CI
J Vasc Surg; 2021 Mar; 73(3):911-917. PubMed ID: 33038480
[TBL] [Abstract][Full Text] [Related]
18. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
Reijnen MMPJ; van Wijck I; Zeller T; Micari A; Veroux P; Keirse K; Lee SW; Li P; Voulgaraki D; Holewijn S
J Endovasc Ther; 2019 Jun; 26(3):305-315. PubMed ID: 30931726
[TBL] [Abstract][Full Text] [Related]
19. Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience.
Lee YJ; Kook H; Ko YG; Yu CW; Joo HJ; Ahn CM; Choi D
Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):287-295. PubMed ID: 33223281
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study.
Secemsky EA; Song Y; Sun T; Johnson CG; Gatski M; Wang L; Farb A; Lee RE; Shaw A; Xu J; Yeh RW
Circulation; 2023 Apr; 147(17):1264-1276. PubMed ID: 36866664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
